Bone cancer is a rare form of cancer that can affect any bone in the body. Two types of bone cancer are multiple myeloma and bone sarcomas. Bone cancers can also happen when tumors that start in other organs, such as breasts, lung, and prostate, metastasize (spread) to the bone. Up to 70% of advanced breast and prostate cancers metastasize to the bone. Multiple myeloma is the most common type of bone cancer. The two most common bone sarcomas are osteosarcoma, which develops in new tissue in growing bones, and chondrosarcoma, which develops in cartilage. Osteosarcoma occurs more frequently in people ages 10 to 20, while chondrosarcoma occurs more often in adults.
Bone cancer is accompanied by the following signs and symptoms:
People with the following conditions or characteristics may be at risk for developing multiple myeloma:
People with the following conditions or characteristics may be at risk for developing osteosarcoma:
If you have symptoms associated with bone cancer, you should see your health care provider. It's helpful to remember that many symptoms of bone cancer are also associated with other, less serious health conditions. In addition to taking a personal and family medical history, your health care provider may suggest a blood test to measure the level of alkaline phosphate, an enzyme that increases when a tumor causes production of abnormal bone tissue. X-rays and other imaging procedures can show the location, size, and shape of a bone tumor. New research suggests that combination positron emission tomography (PET) and computed tomography (CT) may be the most sensitive technique for detecting bone cancers. Not all tumors are cancer. A biopsy -- the removal of a sample of tissue from the bone tumor -- will reveal whether cancer is present.
The treatment plan depends on the type, size, location, and stage of the cancer, as well as the patient's age and general health.
Your health care provider may prescribe the following therapies:
Surgery is usually performed after chemotherapy to shrink the tumor and reduce the risk of recurrence. If chemotherapy is not likely to alter the course of the cancer, surgery or amputation may be the first part of the treatment plan. With multiple myeloma, a physician may perform a bone marrow transplant. With bone sarcomas, surgery is usually the main treatment. In most cases, chemotherapy has made limb-sparing surgery possible and amputation unnecessary.
A comprehensive treatment plan for bone cancer may include a range of complementary and alternative therapies. Make sure to inform your health care provider about the herbs and supplements you are taking. Some supplements can interfere with conventional cancer therapies, so always work with a qualified health care professional, and tell all of your providers about every herb, supplement, medication, and treatment you are using.
Various nutrients and herbs may be beneficial in dealing with bone cancer. But many may also interfere with conventional treatment. Work with a physician who is trained in the use of natural therapies for cancer care, and keep all of your providers informed about any and all supplements or regimens you are considering.
Following these nutritional tips may help reduce symptoms:
Although few studies have examined the effectiveness of specific homeopathic therapies, professional homeopaths may consider the following remedies for the treatment of bone cancer based on their knowledge and experience. Before prescribing a remedy, homeopaths take into account a person's constitutional type, includes your physical, emotional, and psychological makeup. An experienced homeopath assesses all of these factors when determining the most appropriate treatment for each individual. You should only use homeopathic treatment, especially in the case of cancer, under the guidance of a licensed and certified homeopath.
While acupuncture does not treat cancer, evidence suggests it can be a valuable therapy for cancer-related symptoms, particularly the nausea and vomiting that often accompany chemotherapy treatment. Studies show that acupuncture may help reduce pain and shortness of breath. Acupressure (pressing on rather than needling acupuncture points) may also help control breathlessness. Patients treat themselves using this technique.
Some acupuncturists prefer to work with a patient only after the completion of conventional medical cancer therapy. Others provide acupuncture or herbal therapy during active chemotherapy or radiation. Acupuncturists treat cancer patients based on an individualized assessment of the excesses and deficiencies of qi (energy) located in various meridians. In many cancer-related cases, a qi deficiency is detected in the spleen or kidney meridians.
Chiropractors will not perform spinal manipulation over areas of the body where bone cancer is present. But they may use this procedure over areas that are free of bone cancer in an attempt to relieve pain associated with the condition.
Patients with multiple myeloma generally live for 15 months to 5 years. Complications may include heart attack, lung disease, diabetes, and stroke. With bone sarcomas, 65% to 75% of patients experience long-term survival, and almost everyone who is treated with limb-sparing surgery ends up with an arm or leg that is painless and works well. Potential complications include those arising from surgery and possible spread of the cancer to the lungs.
Your health care provider will see you regularly to check for complications, and to make sure the cancer has not returned. You may have frequent CT scans of the lungs and bone scans and x-rays of the arm or leg to ensure the tumor hasn't come back or spread to the lungs.
Bast A, Haenen GR. Lipoic acid: a multifunctional antioxidant. Biofactors. 2003;17(1-4):207-213. PMID: 12897442 www.ncbi.nlm.nih.gov/pubmed/12897442.
Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy--a pilot study. Support Care Cancer. 2005;13(4):270-274. PMID: 15583950 www.ncbi.nlm.nih.gov/pubmed/15583950.
Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506. PMID: 16732220 www.ncbi.nlm.nih.gov/pubmed/16732220.
Boros LG, Nichelatti M, Shoenfeld Y. Fermented wheat germ extract (Avemar) in the treatment of cancer and autoimmune diseases. Ann N Y Acad Sci. 2005;1051:529-542. PMID: 16126993 www.ncbi.nlm.nih.gov/pubmed/16126993.
Buijs Jt, van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett. 2009;273(2):177-193. PMID: 18632203 www.ncbi.nlm.nih.gov/pubmed/18632203.
Cabrera C, Artacho R, Gimenez R. Beneficial effects of green tea--a review. J Am Coll Nutr. 2006;25(2):79-99. PMID: 16582024 www.ncbi.nlm.nih.gov/pubmed/16582024.
Dawson-Hughes B. Calcium and protein in bone health. Proc Nutr Soc. 2003;62(2):505-509. PMID: 14506898 www.ncbi.nlm.nih.gov/pubmed/14506898.
Doron S, Gorbach SL. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther. 2006;4(2):261-275. PMID: 16597207 www.ncbi.nlm.nih.gov/pubmed/16597207.
Doroshow J. Malignant tumors of bone, sarcomas, and other soft tissue neoplasms. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier; 2016;chap 202.
Dryden GW Jr, Deaciuc I, Arteel G, McClain CJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep. 2005;7(4):308-316. PMID: 16042916 www.ncbi.nlm.nih.gov/pubmed/16042916.
Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol. 2007;4(1):42-55. PMID: 17183355 www.ncbi.nlm.nih.gov/pubmed/17183355.
Goggs R, Vaughan-Thomas A, Clegg PD, et al. Nutraceutical therapies for degenerative joint diseases: a critical review. Crit Rev Food Sci Nutr. 2005;45(3):145-164. PMID: 16048146 www.ncbi.nlm.nih.gov/pubmed/16048146.
Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier; 2016.
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29(9):1125-1132. PMID: 21343556 www.ncbi.nlm.nih.gov/pubmed/21343556.
Hicks RJ, Ware RE, Lau EW. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging. 2006;6:S52-S62. PMID: 17114079 www.ncbi.nlm.nih.gov/pubmed/17114079.
Kelemen LE, Cerhan JR, Lim U, et al. Vegetables, fruit, and antioxidant-related nutrients and risk of non-Hodgkin lymphoma: a National Cancer Institute-Surveillance, Epidemiology, and End Results population-based case-control study. Am J Clin Nutr. 2006;83(6):1401-1410. PMID: 16762953 www.ncbi.nlm.nih.gov/pubmed/16762953.
Klein A, Olendrowitz C, Schmutzler R, et al. Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett. 2009;276(2):212-220. PMID: 19114293 www.ncbi.nlm.nih.gov/pubmed/19114293.
Labinskyy N, Csiszar A, Veress G, et al. Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr Med Chem. 2006;13(9):989-996. PMID: 16611080 www.ncbi.nlm.nih.gov/pubmed/16611080.
Lichtenstein AH, Russell RM. Essential nutrients: food or supplements? Where should the emphasis be? JAMA. 2005;294(3):351-358. PMID: 16030280 www.ncbi.nlm.nih.gov/pubmed/16030280.
Mackiewicz-Wysocka M, Pankowska M, Wysocki PJ. Progress in the treatment of bone metastases in cancer patients. Expert Opin Investig Drugs. 2012;21(6):785-795. PMID: 22500564 www.ncbi.nlm.nih.gov/pubmed/22500564.
MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA. 2006;295(4):403-415. Review. PMID: 16434631 www.ncbi.nlm.nih.gov/pubmed/16434631.
Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain. 2013;154 Suppl 1:S54-S62. PMID: 23916671 www.ncbi.nlm.nih.gov/pubmed/23916671.
Montiel-Ruiz RM, Acosta-Gonzalez RI, Jimenez Andrade JM. Bone cancer pain: from preclinical pharmacology to clinical trials. Gac Med Mex. 2013;149(2):204-211. PMID: 23652187 www.ncbi.nlm.nih.gov/pubmed/23652187.
Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495-505. PMID: 12480795 www.ncbi.nlm.nih.gov/pubmed/12480795.
Tsuya A, Fukuoka M. Bone metastases in lung cancer. Clin Calcium. 2008;18(4):455-459. PMID: 18379026 www.ncbi.nlm.nih.gov/pubmed/18379026.
Usui T. Pharmaceutical prospects of phytoestrogens. Endocr J. 2006;53(1):7-20. PMID: 16543667 www.ncbi.nlm.nih.gov/pubmed/16543667.
Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J. 2005;46(5):585-596. PMID: 16259055 www.ncbi.nlm.nih.gov/pubmed/16259055.
Reviewed By: Steven D. Ehrlich, NMD, Solutions Acupuncture, a private practice specializing in complementary and alternative medicine, Phoenix, AZ. Review provided by VeriMed Healthcare Network. Also reviewed by the A.D.A.M Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2022 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.